Regulatory and clinical considerations for biosimilar oncology drugs

Biological oncology products are integral to cancer treatment, but their high costs pose challenges to patients, families, providers, and insurers. The introduction of biosimilar agents—molecules that are similar in structure, function, activity, immunogenicity, and safety to the original biological...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Lancet Oncol
Hoofdauteurs: Bennett, Charles L, Chen, Brian, Hermanson, Terhi, Wyatt, Michael D, Schulz, Richard M, Georgantopoulos, Peter, Kessler, Samuel, Raisch, Dennis W, Qureshi, Zaina P, Lu, Z Kevin, Love, Bryan L, Noxon, Virginia, Bobolts, Laura, Armitage, Melissa, Bian, John, Ray, Paul, Ablin, Richard J, Hrushesky, William J, Macdougall, Iain C, Sartor, Oliver, Armitage, James O
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: 2014
Onderwerpen:
Article
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4404762/
https://ncbi.nlm.nih.gov/pubmed/25456378
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(14)70365-1
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items